SIR-Spheres Y-90 resin microspheres

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:Medicine
gptkbp:administered_by catheter
gptkbp:administration_time 1-2 hours
gptkbp:approves gptkb:FDA
gptkbp:availability hospital pharmacies
gptkbp:clinical_trial ongoing
ongoing studies
gptkbp:clinical_use oncology
gptkbp:collaborations academic institutions
gptkbp:collection clinical registries
gptkbp:contains Yttrium-90
gptkbp:contraindication severe liver disease
extrahepatic disease
gptkbp:developed_by gptkb:Sirtex_Medical
gptkbp:dosage_form microspheres
gptkbp:duration as needed
single session
gptkbp:eligibility good performance status
localized liver tumors
no significant portal hypertension
gptkbp:emissions_standard beta radiation
gptkbp:events blood tests
imaging studies
gptkbp:first_introduced gptkb:2002
gptkbp:future_prospects long-term effects
combination therapies
new delivery methods
https://www.w3.org/2000/01/rdf-schema#label SIR-Spheres Y-90 resin microspheres
gptkbp:invention patented
gptkbp:is_targeted_at liver tumors
gptkbp:manufacturer gptkb:Australia
gptkbp:marketed_as gptkb:SIR-Spheres
gptkbp:mechanism_of_action delivers radiation directly to tumors
gptkbp:packaging sterile vials
gptkbp:price high
gptkbp:provides_guidance_on recommended for certain patients
gptkbp:recruitment multidisciplinary team
gptkbp:regulatory_compliance gptkb:CE_mark
gptkbp:research_focus liver cancer treatment
gptkbp:route_of_administration intra-arterial
gptkbp:safety_features generally well tolerated
gptkbp:shelf_life 2 years
gptkbp:side_effect fatigue
nausea
abdominal pain
liver dysfunction
gptkbp:storage room temperature
gptkbp:treatment gptkb:hepatocellular_carcinoma
reduced symptoms
monitored over time
improved survival rates
tumor shrinkage
metastatic liver cancer
gptkbp:used_for radioembolization
gptkbp:bfsParent gptkb:SIR-Spheres
gptkbp:bfsLayer 9